3-Methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry in mexican population. by Rangel Córdova, Enid Alda et al.
1665-5796 © 2010 Revista Medicina Universitaria. Facultad de Medicina UANL. Publicado por Elsevier México. Todos los derechos reservados.
Medicina Universitaria 2009;11(45):238-242
www.elsevier.com.mx
medicina
universitaria
Corresponding author: Dra. Enid Alda Rangel Córdova. Departamento de Genética, Facultad de Medicina y Hospital Univer-
sitario Dr. José Eleuterio González de la UANL. Avenida Francisco I. Madero y Gonzalitos s/n, Colonia Mitras Centro. C. P. 
64460. Monterrey, Nuevo León, México. Telephone: (+52 81) 8329 4217. E-mail: enidcor2001@hotmail.com
ORIGINAL ARTICLE
3-Methylcrotonyl-CoA carboxylase deficiency detected  
by tandem mass spectrometry in mexican population
Enid Alda Rangel-Córdova, Laura Elia Martínez-de Villarreal, Rosario Torres-
Sepulveda
Genetics Department Dr. José Eleuterio González School of Medicine and University Hospital of the UANL 
(Departamento de Genética. Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González de la UANL)
Received: november, 2009. Accepted: november, 2009
Abstract
Tandem mass spectrometry (MS/MS) was introduced to expand newborn screening in 
Nuevo Leon, Mexico. This has permitted an increase in the diagnosis of many metabolic 
disorders including isolated 3 methylcrotonyl CoA carboxylase deficiency (3 MCC).
Detection of an elevation of C5OH by MS/MS is associated with leucine catabolism di-
sorders; false positive results are related with maternal transfer or immaturity of the 
enzymatic systems. The confirmatory diagnosis is based on organic acids test in urine 
and decreased enzyme activity in fibroblasts. We report three cases of abnormal C5OH 
in among 42 264 newborns (1:14000).1 The diagnosis was confirmed in only one child 
(~1:40 000). The incidence of 3 MCC deficiency in our state is similar to that of other 
populations. This is the first report about the incidence of this disorder in newborns in 
a Mexican population.
Deficiencia de 3 metilcrotonil CoA carboxilasa detectada por medio de espectrome-
tría de masa en tandem en la población mexicana
Resumen
La metodología de espectrometría de masas en tandem (MS/MS) se introdujo para am-
pliar el tamizaje neonatal en Nuevo León, México. Esto ha permitido un incremento en 
el diagnóstico de un mayor número de trastornos metabólicos, incluyendo el trastorno 
causado por la deficiencia aislada de 3 Metilcrotonil CoA Carboxilasa (3 MCC).
La detección de la elevación del analito C5OH por MS/MS se asocia a un trastorno del ca-
tabolismo de la leucina, resultados falsos positivos se relacionan con paso trasplacentario 
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o inmadurez de los sistemas enzimáticos. La confirmación del diagnóstico se basa en el 
examen de ácidos orgánicos en orina y en la disminución de la actividad enzimática en 
fibroblastos. Reportamos tres casos de C5OH anormal de un total de 42 264 recién nacidos 
tamizados en el estado (1:14000).1 El diagnóstico se confirmó en un neonato solamente 
(~1:40 000). La incidencia de la deficiencia de tres MCC en nuestro estado es similar al de 
las otras poblaciones. Este es el primer reporte acerca de la incidencia de este trastorno 
en neonatos en la población mexicana.
Introduction
Isolated 3-Methylcrotonyl-CoA Carboxylase deficiency (3-
MCC) is an inborn error of leucine catabolism inherited 
in an autosomal recessive pattern.1 In 1997 only 26 cases 
had been reported.2 Since the introduction of MS/MS to 
newborn screening programs the diagnosis of 3-MCC de-
ficiency has increased. Patients with this disorder show a 
highly variable clinical phenotype, ranging from asymp-
tomatic detected when the family is tested because a 
newborn is diagnosed with 3-MCC deficiency to a severe 
clinical presentation that includes recurrent episodes of 
vomiting, lethargy and hypotonia. If untreated, this di-
sorder can lead to developmental delay, seizures, coma 
and death. Early detection and lifelong management may 
prevent many of the complications that are often trigge-
red by increased ingestion of proteins or infection. The 
metabolic stress to which these individuals are exposed 
is an important factor in the onset of the disease and 
the variability of symptoms. The diagnosis is made by 
a characteristic biochemical profile that includes plas-
ma elevation of 3-hydroxyisovaleryl-carnitine (C5OH) 
and low levels of carnitine detected by MS/MS, as well 
as increased urine levels of 3-methylcrotonyl-glycine (3 
MCG) and 3-hydroxyisovaleric acid (3-HIVA) detected by 
gas chromatography-mass spectrometry (GC/MS). The 
confirmatory test is based on the detection of decreased 
enzyme activity in white cells or fibroblasts. The analy-
te C5OH is also positive in other leucine and isoleucine 
disorders such as 3-Methylglutaconic hydratase (MGA), 
Hydroxy-3-methylglutaryl-CoA lyase (HMG), 2-Methyl-3-
hydroxybutyryl- CoA Dehydrogenase, beta-ketothiolase 
deficiency, multiple carboxylase deficiency and that due 
to maternal transfer or liver immaturity in the newborn. 
The introduction of tandem mass spectrometry (MS/
MS) to expand the neonatal screening program in Nue-
vo Leon, a state in northeastern Mexico, has eliminated 
several of the problems associated with previous scree-
ning technology such as high false positive rates, the high 
cost of individual testing and the performance of a single 
test to diagnose each disease was time consuming.3 This 
has permitted the early detection of a greater number 
of amino acid, organic acid and fatty acid oxidation di-
sorders.
In 2003 Koeberl et al4 reported 8 cases of 3-MCC in 
North Carolina with a higher incidence among Hispa-
nics. This encouraged us to study the incidence of 3-MCC 
deficiency in our population. In this paper we report the 
findings of abnormal results of C5OH detected by MS/MS 
associated with isolated 3-Methylcrotonyl-CoA Carboxyla-
se deficiency (3-MCC).
Materials and methods
From 2002 to 2004, all the hospitals belonging to the Se-
cretariat of Health of the state of Nuevo Leon started a 
pilot study using MS/MS in the newborn screening pro-
gram. There are around 90,000 births per year in Nuevo 
Leon and one fourth of them are born in hospitals belon-
ging to the State Secretariat of Health.
Samples: Blood samples were obtained by heel prick 
collected during the first 24 hours of life spotted on filter 
paper cards (S&S 903) and allowed to dry. All cards had 
the following data: mother’s name, newborn´s DOB, hos-
pital of birth, gestational age, sex, weight, height, breast 
or bottle feeding, date and hour. Samples were sent to 
the Genetics Department of the Medical School, Autono-
mous University of Nuevo Leon. Samples were extracted 
and processed according to standard methods and if one 
flagged for abnormal elevation of 3-hydroxyisovaleryl-
carnitine (C5OH) the newborn was retested at 2 to 3 
weeks of age. If C5OH levels were again elevated, follow-
up tests such as a plasma acylcarnitine profile and urine 
organic acids were obtained according to the standard 
algorithm for the diagnosis of isolated 3-MCC deficiency.5 
Family members were also tested.
Preparation of sample: a blood specimen is punched 
into a 1/8-inch disk (3 uL of blood on filter paper). Each 
disk is placed into wells of a 96-well microtiter plate. The 
disks are mixed in methanol containing 12 stable isotope 
internal standards of acylcarnitines and 12 stable isoto-
pe internal standards of amino acids (NeoGram Amino 
Acids and Acylcarnitines Tandem Mass Spectrometry Kit). 
The plates are incubated at 30o C and shaken at 750 rpm 
for 30 minutes. A solution (50 uL) of hydrochloric acid in 
anhydrous n-butanol is added to each well, mixed and 
sealed; the metabolites with deuterated internal stan-
dards are converted into the corresponding n-butyl esters 
by heating at 65 oC for 30 minutes.
MS/MS: Amino acids and acylcarnitines (AC) are analy-
zed as butyl esters by using MS/MS triple-quadropole API 
2000 (PerkinElmer Sciex) that is connected with a pump 
and autosampler 200/ PerkinElmer. Briefly, the analysis is 
carried out on small aliquots (3 uL) of each reconstituted 
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specimen that are injected into an ion chamber; each AC 
is calculated on the basis of its stable-isotope deuterium 
compound.
All data were obtained and processed utilizing Analyst 
software and the NeoGram database. The mass spectrum 
is converted to a significant clinical result by calculating 
the concentration of each analyte. The results are ex-
pressed in uM/L.
The normal values for our population were previously 
obtained, the normal value of C5OH was established at 
0.054-1.2 uM/L and all patients with values >3 SD were 
considered abnormal and another sample was requested 
in order to confirm the presumptive abnormality.6 
GC/MC analysis: Urine organic acid determination 
was performed in all newborns with isolated elevations of 
C5OH in the newborn screening. Increased levels of urine 
3 methylcrotonylglycine (3 MCG) and 3-hydroxyisovaleric 
acid (3-HIV) established the diagnosis of 3-MCC deficien-
cy. GC/MC analysis was performed in accordance with the 
standard technique that is well-documented by Honour.7
Results
A total of 42,264 newborns were screened. We found 3 cases 
of elevation of C5OH (Table 1). All individuals were con-
tacted and referred to the Genetics Department for a 
complete medical evaluation.
Clinical description 
Patient 1 is a full-term female neonate of non-consan-
guineous parents, normal delivery, weight of 3.730 Kg, 
height of 52 cm.  The mother had one previous misca-
rriage and 4 normal children. The neonatal physical exam 
was normal and the baby was discharged from the hospi-
tal at 24 hours. An elevation of C5OH of 6.8 μMol/L (5x 
normal value) and low free carnitine was reported (Table 
1).  The second sample taken at 21 days of life was also 
abnormal (4.8 x normal value).  The baby was referred to 
the Genetics Department. The urine organic acids (GC/
MS) reported high levels of 3 methylcrotonylglycine, and 
3-hydroxyisovaleric acid (Table 1). The mother and all 
the family were negative in the MS/MS test.
Patient 2 is a full-term male baby of non-consangui-
neous parents, negative family history, normal delivery, 
weight of 3.050 Kg, height 50 cm, physical exam was nor-
mal and he was discharged at 24 hours;  the C5OH level 
was abnormal at 2.37 μMol/L (2X). A second sample taken 
at 21 days was also reported at 4.93 μMol/L (4X). Urine 
organic acids and free carnitine blood levels were within 
normal values. Despite normal results of urine organic 
acids, C5OH persisted elevated until 5 months of age. Af-
ter that, blood levels of C5OH normalized. His family was 
tested in order to rule out the possibility of asymptomatic 
3-MCC deficiency, the results were normal.
Patient 3 is a full-term female baby, normal delivery, 
of non-consanguineous parents, family history negative, 
weight of 3.400 Kg, height of 52 cm, physical exam was 
normal and she was discharged at 24 hours. Levels of 
C5OH were 2.91 μMol/L (2.4 times elevated), free carniti-
ne was normal. A second sample taken at 15 days showed 
a significant decrease of C5OH levels; blood free carnitine 
and urine organic acids were at normal levels. Her mo-
ther was tested and her results are shown as patient 4.
Patient 4 is a 35 year old female, whose C5OH va-
lues was doubled and free carnitine was below normal. 
Her first test was taken 4 weeks after her baby was born 
and the results were 14.12 μ Mol/L (11.8 times) eleva-
ted); free carnitine was low. A second test was taken at 
a one month interval showing almost the same values 
(C5OH = 14.7 μMol/L and low free carnitine). Results 
are shown in Table 1. She denied symptoms suggesti-
ve of 3MCC deficiency, such as fatigue, muscle cramps 
or weakness and also denied episodes of hypoglycemia or 
epilepsy. Her physical exam was normal except for grade 
1 obesity. The urine organic acids showed abnormal levels 
of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine 
which suggested isolated 3-methylcronotonyl-CoA car-
boxylase deficiency.
These patients were followed every 30 days for 18 
months, focusing on cases 1 and 4. Patient 1 with a res-
tricted protein diet of 2 gr. /Kg/day and carnitine PO 50 
mg/Kg/day is developing and growing well. Her weight, 
height and head circumference are normal. She has 
had episodes of viral gastroenteritis and also a common 
cold and she did well without complications such as 
Table 1. Results
C5OH
0.054-1.2 uMol/L
1st  sample
C5OH
2nd sample
Carnitine
(CO) free
18-85 uMol/L
Urine organic acids:
3-hydroxyisovaleric acid and   
3-methylcrotonylglycine
Age at detection
Case # 1 6.8 5.79 10.0 positive newborn
Case # 2 2.37 4.93 normal normal newborn
Case # 3 2.91 1.3 normal normal newborn
Case # 4 14.12 14.7 6.0 positive adult
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metabolic acidosis or dehydration. All the infants are cu-
rrently healthy. Growing and developing normally. The 
adult patient is asymptomatic. 
Discussion
The primary aim of a newborn screening program is the 
early detection and treatment of clinically important di-
sorders in order to minimize morbidity and mortality in 
early childhood.
The incidence of 3-MCC deficiency depends on the 
ethnic group screened. Before the era of expanded new-
born screening by MS/MS, Weisman3 in 1998 had reported 
26 cases of 3-MCC deficiency corroborated clinically and 
by urine organic acids. Wilken8 in 1998 reported 3 cases of 
MCC deficiency detected by MS/MS in newborn screening 
in Australia, although in his experience, he has not seen a 
symptomatic patient with this disorder.
Koeberl5 et al 2003 reported an incidence of 1/64000, 
in North Carolina mainly in Hispanics. He detected eight 
newborns with 3-MCC deficiency; three of them (37.5%) 
were Hispanics. The New England Program reported an 
incidence of 1/60,0009 while Rashed after ten years of 
screening in Saudi Arabia found only one case.4 In our stu-
dy the incidence of 3-MCC deficiency is higher than in 
Caucasians. In our report one baby had the disease while 
in the others elevation of C5OH was due to liver imma-
turity (Case 2) and maternal transfer (Case 3). Case  4 
confirmed the importance of screening the family in or-
der to provide genetic counseling.
It is of note that case 1 and 4, in which the disease 
was confirmed, abnormal levels of C5OH were higher than 
in the other two cases. Although it is possible that baby 
1 may never have clinically significant disease, long-term 
follow up and treatment as described in symptomatic ca-
ses is necessary.  The adult case in this report probably 
has a benign disease because despite the stress of giving 
birth, she did not present metabolic decompensation or 
any kind of symptom related with this disorder.
There are controversial issues regarding the need 
for treating these patients. Wilken (2003)8 excluded 
the report of positive cases of 3-MCC in Australia´s 
newborn screening program because he considered is a 
benign disease. Mourmans (1995),10 and Lehnert (1996)11
also reported it as a benign condition and Gibson (1998)12 
reported positive asymptomatic cases of siblings and 
mothers of infants detected by newborn screening. 
Nevertheless, there are many other publications 
reporting severely ill patients with symptomatic 3-MCC 
deficiency.3,12-14
The outcome for 3-MCC deficiency is highly varia-
ble. Catastrophic acute presentations include severe 
hypoglycemia (Oude et al 2005)13 Reye-like symptoms 
or neurological non-acute symptoms such as psychomo-
tor retardation, hypotonia, arreflexia, failure to thrive 
and leukodystrophy as described by Kremer (2002).14 
Different presentations in a single family have been des-
cribed by Visser15 in which he reported an infant with 
failure to thrive, gastro-esophageal reflux, hypertonia 
and dilated cardiomyopathy associated with carnitine 
deficiency, her brother had only developmental delays and 
their father was asymptomatic. These reflect the variable 
expressiveness of the disease.
Urinary organic acid analysis usually enables phy-
sicians to make the diagnosis, based on the finding of 
characteristic analytes. Confirmation of 3-MCC deficiency 
based on the determination of enzymatic activity in lym-
phocytes or fibroblasts is desirable; however, Koeberl,5 
Roschinger16 and Van Hove17 have reported a wide range 
of results in the enzymatic activity that are not related to 
the symptoms and the organic acid levels. For the above 
mentioned reasons the determination of enzymatic acti-
vity could be unnecessary for the diagnosis. We concluded 
that the presence of C5OH in blood and of the organic 
acids 3-hydroxyisovaleric acid and 3-methylcrotonylglyci-
ne in urine would be enough to confirm the disease.
This is the first report of 3-MCC deficiency in Mexico. 
In order to know what would be the most common clinical 
phenotype in our population it is necessary to introduce 
the expanded newborn screening to other states of the 
country.
We conclude that the introduction of MS/MS techno-
logy in newborn screening programs will detect additional 
inborn errors of metabolism that otherwise remain un-
diagnosed, such as 3-MCC deficiency, which is usually not 
tested in many newborn screening programs. This has 
enabled us to study this disease in our population in order 
to compare it with the literature. In very symptomatic 
patients tandem mass spectrometry is a rapid screening 
test that should be included early in the diagnostic work 
up of metabolic disorders.
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